Project Grant R01HL187855
Award Date 8/1/26
Completion Date 5/31/30
Dollars Obligated $551K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
University City, MO 63130, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Washington University $764,681 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 1, 2026, to conduct research into a multipotent fibroblast population and platelet-derived growth factor receptor beta–dependent immuno-fibrotic responses in heart failure. The research addresses cardiac fibrosis and left ventricular dysfunction in heart failure by investigating a novel population of stem cell antigen-1–expressing,...
- The National Heart, Lung, and Blood Institute awarded the University of Southern California $240,206 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 1, 2026, to engineer therapeutically programmed monocytes that adaptively immunomodulate the post-infarction myocardial microenvironment toward cardiac repair and regeneration. The award funds development of smart monocytes using synnotch receptor circuits that detect inflammation and respond by secreting...
- The National Heart, Lung, and Blood Institute awarded The Washington University $803,772 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the mitochondrial calcium uniporter in platelet function and thrombosis. The research addresses ischemic stroke prevention through basic and translational science. Approximately 700,000 people in the United States experience ischemic stroke annually, and current acute treatments restrict...
- The National Heart, Lung, and Blood Institute awarded The Trustees of the University of Pennsylvania $632,081 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop conformation-sensitive platelet-hitchhiking lipid nanoparticles for targeted delivery of mRNA and small interfering RNA to infarcted heart tissue following myocardial infarction. The project addresses therapeutic limitations in post-infarction recovery by engineering lipid nanoparticles to...
- The National Heart, Lung, and Blood Institute awarded Cedars-Sinai Medical Center $1.379 million on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cardioprotective mechanisms of Y RNA signaling in macrophages as a potential therapeutic approach to myocardial infarction. The research dissects how a small non-coding RNA called YREX3—secreted by therapeutically-enhanced cardiac stromal cells—signals macrophages to enhance their capacity for...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services, awarded $1,619,582 to the University of Virginia on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the cardio-splenic axis in acute myocardial infarction and post-MI heart failure. The project examines the immunopathological mechanisms by which plasmacytoid dendritic cells orchestrate post-MI inflammation and cardiac dysfunction. The research team...
- The National Institutes of Health National Heart Lung and Blood Institute awarded $248,999 to The University of Iowa on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support fate-mapping of cardiac monocyte recruitment and specification. The award funds research investigating how diverse macrophage populations obtain their distinct transcriptional profiles following cardiac injury, with the goal of identifying spatiotemporal dynamics of macrophage recruitment...
- The National Institutes of Health National Heart Lung and Blood Institute awarded a $511,680 Project Grant to the University of Illinois under the Cardiovascular Diseases Research program (CFDA 93.837). The grant will fund research from February 2021 through August 2021 to investigate mechanisms by which vascular endothelial cells instruct macrophage fate in inflammatory injury. Specifically, the research will examine how endothelial cell Wnt signaling licenses the differentiation of monocytes...
- The National Heart, Lung, and Blood Institute awarded The Washington University $233,250 under the Cardiovascular Diseases Research program (CFDA 93.837) on June 15, 2026, to investigate the mechanisms by which mycophenolic acid (MPA) induces neutropenia in lung transplant recipients. The research examines how MPA influences neutrophil development, survival, and effector function, with a hypothesis that MPA disrupts metabolic pathways—particularly glycolysis—and alters gene expression during...
- The National Heart, Lung, and Blood Institute awarded The Washington University $680,379 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of sphingolipid biosynthesis during lung infection, specifically examining how SPTLC2, an essential enzyme subunit in sphingolipid synthesis, affects survival during Mycobacterium tuberculosis infection in CD11C+ lung macrophages and dendritic cells. The project addresses immune response mechanisms...